CAR T.

It ends in RT. Over half of patients receiving CAR T therapy for relapsed/refractory lymphoma recur again within a year, one-third of which are local-only failures, suggesting consolidative radiation therapy may be warranted, particularly for high risk lesions (read: >5 cm, SUV >10, or extranodal). | Int J Radiat Oncol Biol Phys 2021